0.0950CAD0.00%Mkt Cap: 30.11M CADP/E: —Last update: 2026-05-26
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap30.11M CAD
Enterprise Value115.83M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.63M CAD
Revenue/Share—
Last Price0.0950 CAD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.45
PEG—
EV/EBITDA-25.86
EV/Revenue—
P/S—
P/B-0.15
EPS (TTM)-0.04
EPS (Forward)-0.22
52W Range
0.040021% of range0.3000
52W High0.3000 CAD
52W Low0.0400 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE9.34%
ROA-103.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.89M CAD
CapEx (TTM)472.00K CAD
FCF Margin—
FCF Yield-5.19%
Net Debt85.79M CAD
Net Debt/EBITDA-19.15
Balance Sheet
Debt/Equity-0.20
Current Ratio0.04
Quick Ratio0.02
Book Value/Sh-0.6719 CAD
Cash/Share0.0000 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.316.17M
Float223.25M
Insiders28.71%
Institutions0.00%
Short Interest
Short Ratio2.3d
Short % Out.0.01%
Shares Short13.11K
Short (prev mo.)14.73K
Technical
SMA 500.1066 (-10.9%)
SMA 2000.1064 (-10.7%)
Beta1.04
S&P 52W Chg28.31%
Avg Vol (30d)19.23K
Avg Vol (10d)11.25K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—